Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain

被引:43
作者
Testa, MA
Turner, RR
Simonson, DC
Krafcik, MB
Calvo, C
Luque-Otero, M
机构
[1] Phase V Technol Inc, Wellesley, MA 02481 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Xeral de Galicia, Santiago De Compostela, Spain
[6] Hosp Clin Madrid, Madrid, Spain
关键词
hypertension; quality of life; antihypertensive therapy; clinical trial; nifedipine GITS; amlodipine;
D O I
10.1097/00004872-199816120-00018
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective Compliance with hypertension treatment is affected by treatment-related factors (complexity, side effects), efficacy and compound-specific effects that impact on quality of life. This study examined the differences in quality of life produced by two once-daily calcium channel blockers using different delivery systems: nifedipine gastrointestinal therapeutic system (GITS) and amlodipine. Design This was a double-blind, double-dummy, randomized clinical trial comparing nifedipine GITS (30 mg) and amlodipine (5 mg) for 24 weeks following a placebo run-in. Clinical, laboratory evaluations and quality-of-life data were assessed at screening, baseline randomization and three times during active therapy. Setting The study was conducted in 13 medical clinics in Spain. Patients The sample comprised 430 screened and 356 randomized patients with mild to moderate hypertension (diastolic blood pressure 95-114 mmHg), Main outcome measures Change in systolic and diastolic blood pressure and in health-related quality of life were the main outcome measures. Results There were no significant differences between active treatment groups in the blood pressure changes (systolic blood pressure: nifedipine GITS -15.5 mmHg; amlodipine -15.7 mmHg), Spontaneous adverse events consistent with calcium channel blockage were not different. The nifedipine GITS group improved in all quality-of-life measures except Sexual Symptom Distress and showed a significantly greater improvement than amlodipine in overall Quality of Life (P < 0.05), General Perceived Health (P< 0.026) and its subscale Vitality (P < 0.019). The amlodipine group declined in overall Quality of Life, General Perceived Health, Vitality and Sleep Disturbance, and significantly in Sexual Symptom Distress (P< 0.045). However, this group improved in self-reported Cognitive Functioning (P= 0.036), Mental Acuity (P< 0.005) and Detachment/disorientation (P= 0.01), Conclusions These results suggest compound-specific effects on quality of life that may be due to differences in the delivery system. Nifedipine GITS is short-acting (2 h half-life) and is delivered continuously over a 24 h period, while amlodipine has a half-life of 40 h, which may produce more sustained low-revel effects, While a more beneficial profile was observed for nifedipine, amlodipine demonstrated potential positive effects on cognitive functioning. (C) Lippincott Williams & Wilkins.
引用
收藏
页码:1839 / 1847
页数:9
相关论文
共 44 条
[1]  
*AM MED ASS, 1997, PRINC OUTC RES OUTC
[2]  
AMERY A, 1985, LANCET, V1, P1349
[3]  
Anderson RB., 1994, DRUG INF J, V28, P89, DOI 10.1177/009286159402800112
[4]  
[Anonymous], 1991, Arch Intern Med, V151, P1413
[5]  
[Anonymous], 1991, JAMA, V265, P3255
[6]  
BANSAL S, 1988, HYPERTENSION, V12, P1
[7]  
BARNES JM, 1989, CURRENT ADV ACE INHI, P159
[8]   THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
CARTER, WB ;
GILSON, BS .
MEDICAL CARE, 1981, 19 (08) :787-805
[9]  
BROGDEN R, 1995, DRUGS, V50, P375
[10]  
Bulpitt C J, 1992, Pharmacoeconomics, V1, P95, DOI 10.2165/00019053-199201020-00006